Postoperative morbidity and mortality in patients receiving neoadjuvant chemotherapy for locally advanced gastric cancers: A systematic review and meta-analysis

• Published in: Medicine (Baltimore) 2018-10, Vol.97 (43), p.e12932-e12932
• Main Authors: Luo, Huiyu, Wu, Liucheng, Huang, Mingwei, Jin, Qinwen, Qin, Yuzhou, Chen, Jiansi
• Format: Article
• Language: English
• Subjects: Chemotherapy, Adjuvant - adverse effects; Chemotherapy, Adjuvant - mortality; Humans; Postoperative Complications - etiology; Postoperative Complications - mortality; Stomach Neoplasms - drug therapy; Stomach Neoplasms - mortality; Stomach Neoplasms - surgery; Systematic Review and Meta-Analysis
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000012932

To investigate the postoperative morbidity and mortality for neoadjuvant chemotherapy (NAC) plus surgery compared with surgery alone. PubMed and Embase were searched to capture the incidence of any postoperative complications, pulmonary complications, anastomotic leakage, surgical site infections, and postoperative mortality in randomized clinical trials comparing NAC plus surgery with surgery alone. The meta-analyses were performed with a random effects model. Nine relevant studies were included. Comparing NAC with surgery alone, there were no increases in any postoperative complications, pulmonary complications, anastomotic leakage, surgical site infections, or postoperative mortality attributable to NAC. Sensitivity analysis suggested a possible increased risk of any postoperative complications compared with surgery alone: the risk difference 0.056 (95% confidence interval -0.032 to 0.145). Severe complications such as anastomotic leakage and pulmonary complications were similar in the 2 groups. NAC for gastric cancer does not increase the risk of postoperative morbidity and mortality compared with surgery alone.